Global Osteoporosis Drug Market By Drug Class (Bisphosphonates, Parathyroid Hormone Therapy Drugs), By Route Administration (Oral and injectable), and By Distribution Channel (Retail Pharmacies, Hospital Pharmacies), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2023-2032

Report Overview

The global osteoporosis drugs market size is expected to be worth around USD 9.8 Bn by 2032 from USD 7.0 Bn in 2022, growing at a CAGR of 3.5% during the forecast period from 2022 to 2032.

A medical condition known as osteoporosis is identified by small bone density, which affects the bones and makes them more porous, making them more vulnerable to fractures. Overproduction of the hormone known as parathyroid results in osteoporosis condition. The condition can result in implacable fractures, which can be harmful to the patient’s health. As a result, treatment, including osteoporosis medications, is necessary, such as Bisphosphonates, selective estrogen inhibitors modulator, parathyroid hormone therapy, calcitonin, and RANK ligand inhibitors of the drugs on the market, which are used to treat osteoporosis condition. These medications can be administrated into the body in a variety of ways.

Market Scope

Drug Class Analysis

The Bisphosphonates Segment Dominated the Market Growth During the Forecast Period

The global osteoporosis Drug market is segmented into various drug classes that made the market growth such as bisphosphonates, selective estrogen inhibitors, modulators, parathyroid hormone therapy, calcitonin, rank ligand inhibitors, and others. Bisphosphonates accounted for the majority of shares in the osteoporosis drugs market as a result, major players increased investments in research and development of innovative novel bisphosphonates.

The market expansion is also driven by the widespread use of bisphosphonates to treat osteoporosis. The rank ligand inhibitors market is anticipated to expand at the fastest rate during the forecast period due to their use to manage bone transformation by acting as a chemoattractant to the bone for tumor cells that accelerate their RANK receptor.

The RANK ligand inhibitor category is anticipated to expand at the highest CAGR over the forecast period. Osteoporosis is treated with rank ligand inhibitors in patients at risk of fracture. The rising the growth development of rank ligand inhibitors is assisted by favorable patient outcomes. Positive patient outcomes can be authorized to fundamental changes in bone metabolism. Rank ligand inhibitors can be combined with other medications to produce a synergistic effect across the complete treatment plan.

By Distribution Analysis

An increased Number of Patient Visits in Hospitals for Osteoporosis Treatment Drives the Hospital Pharmacies Segment

The market is segmented into hospitals pharmacies, retail pharmacies, and online pharmacies according to the distribution channel. Increased in the number of osteoporosis patients demanding treatment in hospitals. Support from the government for the development of hospital pharmacies and other factors that fuel their growth.

By Route Administration

Oral Route of Administration Dominates the Global Osteoporosis  Market

On the basis of the route of administration, the osteoporosis drug is segmented into oral and injectable drugs. Due to the rise in oral drug use, the oral route of administration dominates the market. In addition, the rise in oral medication use is having a positive impact on larger production, which has contributed to the market’s expansion over time.

In contrast, it is anticipated that the injectable route of administration segment will experience faster growth during the forecast period due to the introduction of a new biosimilar that is safer and more user-friendly for osteoporosis treatment.

Key Market Segments

By Product

• Bisphosphonates
• Parathyroid Hormone Therapy Drugs
• Calcitonin
• Selective Estrogen Receptor Modulators
• RANK Ligand Inhibitor
• Others

By Route of Administration

• Oral
• Injectable

By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Sales

Market Dynamics

Drivers

Increasing Healthcare Expenditure Drives the Osteoporosis Drug Market

Healthcare costs are rising worldwide as a result of rising disease prevalence and rising government and non-government initiatives. As a result, healthcare infrastructure is getting better and treatment for a variety of medical conditions is becoming less expensive and easier to get. The Market is expanded by an increase in healthcare awareness, and women’s health maintenance and by the introduction of new products by manufacturers for an increasing share of the market.

Restraints

Adverse Effects and Increased Risk Osteoporosis Drugs Are Restraining the Market Growth

The market’s expansion is being hampered by the adverse effects of anti-inflammatory medications and the absence of convincing evidence to support their effectiveness. Their osteoporosis medication side effects, such as hot flashes, leg cramps, vomiting, and diarrhea, and other factors are limiting the market for osteoporosis medications.

there are some other factors that will restrain the market’s expansion during the forecast period. The factors, such as the drug’s expiration of its patent due to an increase in risk factors. The growth is being hampered by the drugs and other side effects.

Opportunity

Increase in Healthcare Expenditure Leads to Osteoporosis Drug Market

The osteoporosis drug industry is also growing because of the expanding healthcare sectors in a number of emerging economies like China, India, Brazil, and South Africa. New growth opportunities are being utilized by osteoporosis medication. It is absolutely necessary to increase investment in research and development in order to encourage market expansion. The rapidly expanding geriatric population, high patient volumes, and rising public awareness are driving factors that need to improve healthcare industries in these nations.

Governments in these economies are investing more in healthcare facilities and infrastructure as a result. Regional expansion, new product development, industry collaboration, assignment development, and mergers and acquisitions are additional development strategies for gaining a competitive advantage in the global market. Due to a large number of coronary stent applications, it is anticipated that the growing investment in this sector will provide opportunities for market expansion.

Trends

Injectable Drugs are Anticipited Major Market Share During Forecast Period

New and effective diagnostic methods for screening for osteoporosis have emerged as a result of advancements in technology. These devices’ accuracy, simplicity, ease of use, and rapid benefits in screening the high-volume risk groups. This directly increases the number of patients who are being diagnosed with osteoporosis and are receiving treatment.

It is anticipated that the highest rate of growth for injectable osteoporosis medications will occur during the forecast period. This may be primarily because drugs given intravenously do not upset the stomach, and it may be easier for some people to schedule timing or annual infusions than to remember to take pills every week or month. People who are unable to take bisphosphonates orally, such as those with damaged kidney function, can also take them by injection.

COVID-19 Impact Analysis

A Decline in the Number of Tests Performed during COVID-19 Owing to delay in Diagnosis and Treatment

Many osteoporosis patients’ treatment is disturbed or delayed by COVID-19. As a result, an orthopedic committee was established by the American Society for Bone and Mineral Research to manage the treatment of specific diseases during the pandemic. Worldwide, numerous treatments are being examined for COVID-19 treatment efficacy.

Numerous studies have suggested that COVID-19 treatment may benefit from other drugs like osteoporosis, which are used to treat infections. This could expand the market. Denosumab, zoledronate, and calcium, for example, are used to treat both osteoporosis and COVID-19. General treatment of osteoporosis drugs may help reduce the incidence of COVID-19.

Regional Analysis

North America Region accounts for Largest Share During Forecast Period

In North America, the osteoporosis drugs market dominates the largest shares in the market. This is because the number of elderly people, obesity, lifestyle-related diseases, and osteoporosis are all rising in the region. For instance, approximately 10 million people in the United States have osteoporosis, and 34 million people in the United States have low bone density, which increases their risk of fracture due to rising awareness of osteoporosis treatment, and changing lifestyles.

High healthcare costs and drug use for osteoporosis are common in North America. The growing population, shifting lifestyles, rapid urbanization, and rising awareness are all contributing factors to the expansion of the osteoporosis care market in Europe. Compared to hypertension and rheumatoid arthritis, osteoporotic fractures account for slightly more disability-adjusted life years in Europe.

Key Regions

North America

• The US
• Canada
• Mexico

Eastern Europe

• Russia
• Poland
• The Czech Republic
• Greece
• Rest of Eastern Europe

Western Europe

• Germany
• France
• The UK
• Spain
• Italy
• Portugal
• Ireland
• Austria
• Switzerland
• Benelux
• Nordic
• Rest of Western Europe

APAC

• China
• Japan
• South Korea
• India
• Australia & New Zealand
• Indonesia
• Malaysia
• Philippines
• Singapore
• Thailand
• Vietnam
• Rest of APAC

 Latin America

• Brazil
• Colombia
• Chile
• Argentina
• Costa Rica
• Rest of Latin America

Middle East & Africa

• Algeria
• Egypt
• Israel
• Kuwait
• Nigeria
• Saudi Arabia
• South Africa
• Turkey
• United Arab Emirates
• Rest of MEA

Key Players Analysis

There are a number of major players in the osteoporosis medication market, which is comparatively determined by Pfizer Inc., Eli Lily and Company, F. Hoffmann La Roche, Merck & Co. Inc., Amgen Inc., Radius Health Inc., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline PLC, Novartis International AG, and Actavis PLC are among the market leaders at the moment.

Due to the growing combination of common strategies by key players to maintain their competitive position, this industry is anticipated to experience intense competition during the forecast period. High R&D expenditures, unions and achievements, and contracts for drug advancements are additional strategies incorporated.

Recent Development

• In August 2022: Enzene Biosciences Ltd. received Marketing Authorization (MA) for its biosimilar treatment for adults with osteoporosis, denosumab, from the Drug Controller General of India (DCGI).
• In January 2021: The osteoporosis medication Livogiva was introduced to Europe by Theramex, a pharmaceutical company headquartered in London.

Market Key Players

With the presence of many local and regional players, the market for companion diagnostics is fragmented. Market players are subject to intense competition from top market players, particularly those with strong brand recognition and high distribution networks. To stay on top of the market, companies have gained various expansion strategies such as partnerships and product launches.

The following are some of the major players in the global osteoporosis drug Market.

• Amgen Inc.
• Eli Lilly and Company
• Hoffmann-La Roche AG
• Mark and Co. Inc.
• Novartis AG
• Pfizer Inc.
• Radius Health Inc.
• Teva Pharmaceutical Industries Ltd.
• Novo Nordisk A\S
• UCB
• Other key players

Report Scope